- Birinapant
-
- $41.00 / 2mg
-
2026-03-13
- CAS:1260251-31-7
- Min. Order:
- Purity: 99.78%
- Supply Ability: 10g
- Birinapant
-
- $15.00 / 1KG
-
2021-07-02
- CAS:1260251-31-7
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Birinapant Basic information |
| Product Name: | Birinapant | | Synonyms: | Birinapant;Birinapant (TL32711);TL 32711;Birinapant(TL32711)/TL-32711/TL32711/TL-32711;(2S,2'S)-N,N'-[(6,6'-Difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-propanamide;Propanamide, N,N'-[(6,6'-difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-, (2S,2'S)-;(2S,2'S)-N,N'-[(6,6'-Difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-propanamide Birinapant TL 32711;Birinapant (2S,2'S)-N,N'-[(6,6'-Difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-propanamide | | CAS: | 1260251-31-7 | | MF: | C42H56F2N8O6 | | MW: | 806.94 | | EINECS: | | | Product Categories: | Inhibitors;Inhibitor | | Mol File: | 1260251-31-7.mol |  |
| | Birinapant Chemical Properties |
| Melting point | >245oC (dec.) | | Boiling point | 1090.5±65.0 °C(Predicted) | | density | 1.320±0.06(20.0000℃) | | storage temp. | -20°C Freezer | | solubility | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | | pka | 13.99±0.46(Predicted) | | form | Solid | | color | White to Off-White | | InChIKey | PKWRMUKBEYJEIX-AUTGSTJINA-N |
| | Birinapant Usage And Synthesis |
| Description | Birinapant is a bivalent mimetic of the Diablo homolog known as second mitochondria-derived activator of caspase (Smac). It is an antagonist of cellular inhibitor of apoptosis 1 (cIAP1, or BIRC2), cIAP2 (BIRC3), and XIAP (BIRC4), binding each at nanomolar concentrations. Birinapant causes rapid cIAP1 degradation, caspase activation, PARP cleavage, and NF-κB activation in breast cancer cells. It shows in vivo antitumor activity, inducing apoptosis in several types of cancer xenografts in mice. | | Uses | Birinapant is a bivalent SMAC mimetic compound antagonist of TRAF2 associated cIAP1 and cIAP2. | | Definition | ChEBI: Birinapant is a dipeptide. | | Enzyme inhibitor | This rotationally symmetric SMAC mimetic antagonist and anticancer agent (FW = 806.94 g/mol; CAS 1260251-31-7) targets cellular Inhibitor of Apoptosis Protein (or cIAP1; Kd of <1 nM), arguably the most potent mammalian caspase inhibitor, showing single-agent efficacy due to its panIAP antagonism and causing rapid cIAP1 degradation, caspase activation, PARP cleavage, and NF-κB activation. When administered in combination with TNF-α, Birinapant is effective against a melanoma cell line with acquired resistance to BRAF inhibitors | | target | XIAP | | References | [1] JENNIFER L ALLENSWORTH. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.[J]. Breast Cancer Research and Treatment, 2013, 137 2: 359-371. DOI: 10.1007/s10549-012-2352-6
[2] CLEMENS KREPLER. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.[J]. Clinical Cancer Research, 2013, 19 7: 1784-1794. DOI: 10.1158/1078-0432.ccr-12-2518
[3] QUANG-Dé NGUYEN. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging.[J]. Clinical Cancer Research, 2013, 19 14: 3914-3924. DOI: 10.1158/1078-0432.ccr-12-3814 |
| | Birinapant Preparation Products And Raw materials |
|